hydroxyindoleacetic acid and Parkinson Disease studies

(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

Excerpt	Relevance	Reference
"Present study was designed to monitor the cognitive profile of the animals upon repeated administration of reserpine, so as to determine that whether these animals should be used as animal models of Parkinson's dementia."	7.91	Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. ( Haleem, DJ; Ikram, H, 2019)
"The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline."	7.78	6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012)
"Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in the sixth, 13th, and 20th milliliters of CSF in patients with dementia of the Alzheimer's type (DAT) and Parkinson's disease (PD), and in an aliquot of CSF in controls."	7.67	Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. ( Albert, ML; Bird, ED; Direnfeld, LK; Freedman, M; Langlias, PJ; Volicer, L, 1985)
"Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease."	7.67	The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985)
"Ventricular fluid concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), the respective metabolites of dopamine and serotonin, were measured in 57 patients undergoing thalamotomy for relief of movement disorders."	7.66	Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. ( Sharpless, NS; Tabaddor, K; Wolfson, LI, 1978)
"In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions."	5.91	Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023)
"Rapid-onset dystonia-parkinsonism (RDP) is characterized by sudden onset over hours to days of dystonia, dysphagia, dysarthria, and parkinsonism."	5.30	Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. ( Brashear, A; Butler, IJ; Dobyns, WB; Farlow, MR; Hyland, K, 1998)
"In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations."	5.29	Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996)
"Present study was designed to monitor the cognitive profile of the animals upon repeated administration of reserpine, so as to determine that whether these animals should be used as animal models of Parkinson's dementia."	3.91	Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. ( Haleem, DJ; Ikram, H, 2019)
"The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline."	3.78	6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012)
"Tritiated imipramine binding in platelets has been used to evaluate serotonin activity in depression in previous studies."	3.68	Tritiated imipramine binding. A peripheral marker for serotonin in Parkinson's disease. ( Coté, L; Lawton, A; Marder, K; Mayeux, R; Sano, M; Stanley, M; Stern, Y; Williams, J, 1991)
"In four human controls, four cases of Parkinson's disease and three cases of amyotrophic lateral sclerosis analysis of dopamine, noradrenaline, serotonin and the metabolites 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid was performed in various segments of postmortem spinal cord."	3.68	Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. ( Gavranovic, M; Gsell, W; Jellinger, K; Riederer, P; Schmidtke, A; Sofic, E, 1991)
"Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease."	3.67	The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985)
"Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in the sixth, 13th, and 20th milliliters of CSF in patients with dementia of the Alzheimer's type (DAT) and Parkinson's disease (PD), and in an aliquot of CSF in controls."	3.67	Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. ( Albert, ML; Bird, ED; Direnfeld, LK; Freedman, M; Langlias, PJ; Volicer, L, 1985)
"Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex."	3.66	Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981)
"Ventricular fluid concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), the respective metabolites of dopamine and serotonin, were measured in 57 patients undergoing thalamotomy for relief of movement disorders."	3.66	Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. ( Sharpless, NS; Tabaddor, K; Wolfson, LI, 1978)
"We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor."	3.65	Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977)
" The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease."	2.66	Tetrahydrobiopterin and Parkinson's disease. ( Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V, 1989)
"Demented patients with Parkinson's disease, particularly those with concurrent depression, had the lowest values of 5-HIAA."	2.66	The relationship of serotonin to depression in Parkinson's disease. ( Cote, LJ; Mayeux, R; Sano, M; Stern, Y; Williams, JB, 1988)
"Eleven patients with severe Parkinson's disease and on-off-phenomena were included in a controlled double-blind study on the effect of electroconvulsive therapy (ECT)."	2.66	A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. ( Andersen, K; Balldin, J; Gottfries, CG; Granérus, AK; Modigh, K; Svennerholm, L; Wallin, A, 1987)
"It is controversial if early onset Parkinson's disease (EOPD) (onset at < 41 years of age) is Parkinson's disease (PD) occurring at a younger age or a different disease."	2.39	Early onset Parkinson's disease: are juvenile- and young-onset different? ( Muthane, UB; Rao, S; Satishchandra, P; Subbakrishna, D; Subhash, MN; Swamy, HS, 1994)
"Female gender, early age at onset of Parkinson's disease, and greater left brain involvement may also be risk factors."	2.38	Depression and Parkinson's disease: a review. ( Cummings, JL, 1992)
"In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions."	1.91	Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023)
"We developed a diagnostic method for Parkinson's disease by simultaneously analyzing biogenic amines and their metabolites using reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection (RP-HPLC-IPAD) method."	1.48	Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection. ( Hong, SP; Huh, E; Jeong, JS; Oh, M; Oh, MS, 2018)
"Lewy body disorders, including Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), are characterized by profound central and peripheral monoaminergic dysfunction."	1.48	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. ( Aerts, T; De Deyn, PP; Fransen, E; Gerritsen, MJ; Spikman, JM; Van Dam, D; van der Zee, S; van Laar, T; Vermeiren, Y, 2018)
"The symptoms of restless legs syndrome (RLS) have a circadian pattern and central nervous system dopamine has been implicated in the pathogenesis of the condition."	1.35	Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. ( Engelland, S; Kripke, DF; Parsons, L; Poceta, JS, 2009)
"Interest in serotonergic involvement in Parkinson's disease (PD) has focussed recently on the possibility that the remaining serotonin neurons innervating striatum (caudate and putamen) might release dopamine as a 'false transmitter'--an action that could have both beneficial and harmful (e."	1.35	Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. ( Chang, LJ; Furukawa, Y; Guttman, M; Hornykiewicz, O; Kish, SJ; Rajput, A; Tong, J, 2008)
"This syndrome is usually caused by endogenous dopamine deficiency but in these patients was associated with elevated dopamine metabolites in CSF and an unusual eye movement disorder: ocular flutter together with saccade initiation failure."	1.32	Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. ( Assmann, BE; Bräutigam, C; Heales, SJ; Hoffmann, GF; Hyland, K; Robinson, RO; Sharma, R; Surtees, RA; Wevers, RA; Zschocke, J, 2004)
"To determine susceptibility to neuroleptic malignant syndrome (NMS) in patients with PD in relation to central monoamine metabolism."	1.30	Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. ( Hamamoto, M; Katayama, Y; Miyazaki, T; Nagayama, H; Nito, C; Otsubo, K; Terashi, A; Ueda, M, 1999)
"Rapid-onset dystonia-parkinsonism (RDP) is characterized by sudden onset over hours to days of dystonia, dysphagia, dysarthria, and parkinsonism."	1.30	Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. ( Brashear, A; Butler, IJ; Dobyns, WB; Farlow, MR; Hyland, K, 1998)
"In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations."	1.29	Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996)
"There is some evidence that Parkinson's disease (PD) seems to be a heterogenous and generalized brain disorder reflecting a degeneration of multiple neuronal networks, including somatostatinergic neurons."	1.29	Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa. ( Cramer, H; Hamann, GF; Schimrigk, K; Strittmatter, M; Strubel, D, 1996)
"Rapid-onset dystonia-parkinsonism (RDP) is an autosomal dominant disorder characterized by the rapid onset of dystonic spasms and parkinsonism over a period of a few hours to weeks after their onset."	1.29	Variable phenotype of rapid-onset dystonia-parkinsonism. ( Brashear, A; Butler, IJ; Dobyns, WB; Farlow, MR; Kasarskis, EJ, 1996)
"In untreated patients with Parkinson's disease (PD), the total (free and conjugated) serotonin (5-HT) and dopamine (DA) concentrations in the cerebrospinal fluid decreased significantly."	1.29	Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. ( Abe, T; Hamato, H; Takahashi, J; Takahashi, S; Tohgi, H, 1993)
"In contrast to senile dementia of Alzheimer's type SLI was not correlated with dementia scores but with motor disease progression."	1.28	Parkinson's disease and dementia: clinical and neurochemical correlations. ( Cramer, H; Strittmatter, MM, 1992)
"In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than ."	1.28	Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. ( Cramer, H; Kuntzmann, F; Masson, H; Popescu, I; Strubel, D, 1990)
"Among Parkinson's disease (PD) patients complaining of pain, 10 with pain not associated with a motor fluctuation or L-dopa therapy were evaluated."	1.28	The threshold of pain and neurotransmitter's change on pain in Parkinson's disease. ( Matsushima, E; Nishikawa, S; Sano, K; Takahashi, K; Takao, T; Urakami, K, 1990)
" L-DOPA administration, consisting of a daily dosage of 600 mg plus 150 mg aromatic L-amino acid decarboxylase inhibitor was continued in all cases for at least 3 months."	1.28	Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid. ( Araki, H; Kondo, T; Muramoto, S; Narabayashi, H; Nishi, K; Takubo, H, 1989)
"In a prospective study of patients with Parkinson's disease we found a continuum of cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations."	1.28	Coexisting dementia and depression in Parkinson's disease. ( Coté, L; Mayeux, R; Rosenstein, R; Sano, M; Stern, Y; Williams, J, 1989)
"Patients with hypoxic encephalopathy consisted of 5 with apallic syndrome and one patient with Lance-Adams syndrome."	1.28	[Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases]. ( Fukuda, H; Hara, K; Kameyama, M; Nakamura, S; Udaka, F, 1989)
"Among 49 consecutive patients with Parkinson's disease, 40% were depressed according to DSM-III; they had major depression or dysthymic disorder accompanied by sleep disturbance, fatigue, psychomotor retardation, loss of self-esteem, and excessive guilt."	1.27	Clinical and biochemical features of depression in Parkinson's disease. ( Cote, L; Dyrenfurth, I; Frantz, A; Mayeux, R; Stern, Y; Williams, JB, 1986)
"Depression is frequently encountered in Parkinson's disease and was seen to occur in 14 of 26 patients studied."	1.27	Depression and Parkinson's disease: possible role of serotonergic mechanisms. ( Bumbasirević, L; Covicković-Sternić, N; Djuricić, BM; Kostić, VS; Mrsulja, BB; Nikolić, M, 1987)
"Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine."	1.27	Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984)
"The brain content of serotonin in Parkinson's disease is also reduced, but this has not been related to any manifestation of the disorder."	1.27	Altered serotonin metabolism in depressed patients with parkinson's disease. ( Cote, L; Mayeux, R; Stern, Y; Williams, JB, 1984)
"Treatment with tetrabenazine did not significantly alter the metabolite levels in patients in whom it produced either improvement, or side effects."	1.26	CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. ( Davidson, DL; Mawdsley, C; Pullar, IA; Wilson, H; Yates, CM, 1977)
"Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex."	1.26	Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981)
"Two cases of idiopathic orthostatic hypotension are reported, one associated with striato-nigral degeneration (case 1) and the other with Lewy body parkinsonism (case 2)."	1.25	Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases. ( Forno, LS; Langston, JW; Schober, R, 1975)
"Levodopa induced an increase of about 400 fold in urinary DA; DOPAC was increased about 300 fold, 3-MT only about 70 fold, but HVA about 300 fold."	1.25	Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975)

Research

Studies (193)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

The Number All Types of Adverse Events.

Timeframe	Studies, this research(%)	All Research%
pre-1990	139 (72.02)	18.7374
1990's	30 (15.54)	18.2507
2000's	9 (4.66)	29.6817
2010's	12 (6.22)	24.3611
2020's	3 (1.55)	2.80

Authors	Studies
Kaiserova, M	1
Chudackova, M	1
Prikrylova Vranova, H	1
Mensikova, K	1
Kastelikova, A	1
Stejskal, D	1
Kanovsky, P	1
Fathi, M	1
Vakili, K	1
Yaghoobpoor, S	1
Tavasol, A	1
Jazi, K	1
Hajibeygi, R	1
Shool, S	1
Sodeifian, F	1
Klegeris, A	1
McElhinney, A	1
Tavirani, MR	1
Sayehmiri, F	1
Yang, R	1
Ye, S	1
Zhang, S	1
Huang, H	1
Zhang, Y	1
Yang, Y	2
Xie, S	1
He, L	1
Shi, J	1
Oh, M	1
Huh, E	1
Oh, MS	1
Jeong, JS	1
Hong, SP	1
van der Zee, S	1
Vermeiren, Y	1
Fransen, E	1
Van Dam, D	1
Aerts, T	1
Gerritsen, MJ	1
Spikman, JM	1
van Laar, T	1
De Deyn, PP	1
Ikram, H	1
Haleem, DJ	1
Herbert, MK	1
Kuiperij, H	1
Bloem, BR	2
Verbeek, MM	2
Olivola, E	1
Pierantozzi, M	1
Imbriani, P	1
Liguori, C	1
Stampanoni Bassi, M	1
Conti, M	1
D'Angelo, V	1
Mercuri, NB	1
Stefani, A	1
Tong, Q	1
Zhang, L	2
Yuan, Y	1
Jiang, S	1
Zhang, R	1
Xu, Q	1
Ding, J	1
Li, D	1
Zhou, X	1
Zhang, K	1
Miguelez, C	1
Navailles, S	1
Delaville, C	1
Marquis, L	1
Lagière, M	1
Benazzouz, A	1
Ugedo, L	1
De Deurwaerdère, P	1
Pålhagen, S	1
Qi, H	1
Mårtensson, B	1
Wålinder, J	2
Granérus, AK	4
Svenningsson, P	1
Li, XM	1
Ma, HB	1
Ma, ZQ	1
Li, LF	1
Xu, CL	1
Qu, R	1
Ma, SP	1
Nyhlén, J	1
Constantinescu, R	1
Zetterberg, H	1
Liu, J	1
Wang, H	1
Xu, Y	1
Deng, W	1
Zhu, H	1
Qin, C	1
Kolasiewicz, W	1
Kuter, K	1
Berghauzen, K	1
Nowak, P	1
Schulze, G	1
Ossowska, K	1
BARBEAU, A	1
JASMIN, G	1
Abdo, WF	1
De Jong, D	1
Hendriks, JC	1
Horstink, MW	1
Kremer, BP	1
Assmann, BE	1
Robinson, RO	1
Surtees, RA	1
Bräutigam, C	1
Heales, SJ	1
Wevers, RA	1
Zschocke, J	1
Hyland, K	2
Sharma, R	1
Hoffmann, GF	1
Kish, SJ	1
Tong, J	1
Hornykiewicz, O	3
Rajput, A	1
Chang, LJ	1
Guttman, M	2
Furukawa, Y	1
Kääriäinen, TM	1
García-Horsman, JA	1
Piltonen, M	1
Huotari, M	1
Männistö, PT	1
Aguiar, LM	1
Macêdo, DS	1
Vasconcelos, SM	1
Oliveira, AA	1
de Sousa, FC	1
Viana, GS	1
Poceta, JS	1
Parsons, L	1
Engelland, S	1
Kripke, DF	1
Johansson, B	2
Roos, BE	8
Mayeux, R	9
Agnoli, A	2
Ruggieri, S	1
Falaschi, P	1
Baldassarre, M	1
D'Urso, R	1
Forchetti, C	1
Polleri, A	1
Namba, S	1
Ishimitsu, H	1
Nakasone, S	1
Eisler, T	1
Teräväinen, H	1
Nelson, R	1
Krebs, H	1
Weise, V	1
Lake, CR	1
Ebert, MH	4
Whetzel, N	1
Murphy, DL	2
Kopin, IJ	4
Calne, DB	3
Vanderheyden, JE	2
Noel, G	2
Mendlewicz, J	2
Growdon, JH	2
Melamed, E	1
Logue, M	2
Hefti, F	1
Wurtman, RJ	1
Markianos, M	1
Hadjikonstantinou, M	1
Bistolaki, E	1
Burns, RS	2
Chiueh, CC	1
Markey, SP	1
Jacobowitz, DM	1
Cramer, H	4
Warter, JM	1
Renaud, B	1
Stern, Y	8
Cote, L	7
Williams, JB	5
Mena, MA	1
Aguado, EG	1
de Yebenes, JG	1
Tohgi, H	2
Abe, T	2
Takahashi, S	2
Takahashi, J	2
Hamato, H	2
Muthane, UB	2
Swamy, HS	1
Satishchandra, P	2
Subhash, MN	2
Rao, S	1
Subbakrishna, D	1
Brashear, A	2
Farlow, MR	2
Butler, IJ	2
Kasarskis, EJ	1
Dobyns, WB	2
Strittmatter, M	1
Hamann, GF	1
Strubel, D	2
Schimrigk, K	1
Maruyama, W	1
Naoi, M	1
Narabayashi, H	2
Bowenkamp, KE	1
Lapchak, PA	1
Hoffer, BJ	1
Miller, PJ	1
Bickford, PC	1
Iacono, RP	2
Kuniyoshi, SM	1
Ahlman, JR	1
Zimmerman, GJ	1
Maeda, G	1
Pearlstein, RD	1
Yoshida, K	1
Higuchi, H	1
Kamata, M	1
Yoshimoto, M	1
Shimizu, T	1
Hishikawa, Y	1
Moser, A	1
Siebecker, F	1
Vieregge, P	1
Jaskowski, P	1
Kömpf, D	1
Fall, PA	1
Ekman, R	1
Thorell, LH	1
Ueda, M	1
Hamamoto, M	1
Nagayama, H	1
Otsubo, K	1
Nito, C	1
Miyazaki, T	1
Terashi, A	1
Katayama, Y	1
Liu, H	1
Schoonenberg, T	1
Kuniyoshi, S	1
Buchholz, J	1
Meissner, W	1
Paul, G	1
Reum, T	1
Reese, R	1
Sohr, R	1
Morgenstern, R	1
Kupsch, A	1
Abe, K	1
Taguchi, K	1
Wasai, T	1
Ren, J	1
Utsunomiya, I	1
Shinohara, T	1
Miyatake, T	1
Sano, T	1
Shimamoto, H	1
Takasaki, K	1
Shigemori, M	1
Imaizumi, T	1
Ayabe, M	1
Shoji, H	1
Klawans, H	1
Kartzinel, R	2
Chase, TN	17
Perlow, MD	1
Carter, AC	1
Shoulson, I	2
Adolfsson, R	1
Gottfries, CG	4
Winblad, B	1
Korf, J	4
van Praagen, HM	1
Lakke, JP	4
Tabaddor, K	1
Wolfson, LI	3
Sharpless, NS	3
Ouvrier, RA	1
Hutt, CS	1
Snider, SR	1
Fahn, S	1
Davidson, DL	1
Yates, CM	1
Mawdsley, C	1
Pullar, IA	3
Wilson, H	1
Naidu, S	1
Rinne, UK	11
Siirtola, T	4
Sonninen, V	11
Sachdev, KK	1
Singh, N	1
Krishnamoorthy, MS	1
Campanella, G	1
Algeri, S	1
Cerletti, C	1
Dolfini, E	2
Jori, A	2
Rinaldi, F	1
Lenman, JA	3
Turnbull, MJ	3
Reid, A	1
Fleming, AM	1
Marttila, R	3
Allen, N	1
Knopp, W	1
Michel, D	1
Tommasi, M	1
Laurent, B	1
Trillet, M	1
Schott, B	1
Schober, R	1
Langston, JW	1
Forno, LS	1
Robinson, DS	2
McLellan, DL	1
Chalmers, RJ	1
Johnson, RH	1
Birkmayer, W	5
Danielczyk, W	4
Neumayer, E	5
Riederer, P	7
Wesemann, W	1
Cummings, JL	1
Lach, B	1
Grimes, D	1
Benoit, B	1
Minkiewicz-Janda, A	1
Strittmatter, MM	1
Masson, H	1
Popescu, I	1
Kuntzmann, F	1
Fibiger, HC	1
Jakubovic, A	1
Shirakawa, J	1
Tanaka, C	1
Saijoh, K	1
Lindvall, B	1
Olsson, JE	1
Przuntek, H	3
Kuhn, W	2
Bankiewicz, KS	1
Plunkett, RJ	1
Mefford, I	1
Oldfield, EH	1
Urakami, K	1
Takahashi, K	1
Matsushima, E	1
Sano, K	1
Nishikawa, S	1
Takao, T	1
Russ, H	1
Mihatsch, W	1
Gerlach, M	1
Sofic, E	1
Gsell, W	1
Gavranovic, M	1
Schmidtke, A	1
Jellinger, K	1
Sano, M	5
Stanley, M	1
Lawton, A	1
Williams, J	2
Marder, K	1
Perry, EK	1
McKeith, I	1
Thompson, P	1
Marshall, E	1
Kerwin, J	1
Jabeen, S	1
Edwardson, JA	1
Ince, P	1
Blessed, G	1
Irving, D	1
Conte-Devolx, B	1
Grino, M	1
Nieoullon, A	1
Javoy-Agid, F	2
Castanas, E	1
Guillaume, V	1
Tonon, MC	1
Vaudry, H	1
Oliver, C	1
Youdim, MB	1
Parenti, M	1
Flauto, C	1
Parati, E	1
Vescovi, A	1
Groppetti, A	1
Nakamura, S	2
Frantz, A	1
Dyrenfurth, I	1
van Praag, HM	4
Scatton, B	1
Dennis, T	1
L'Heureux, R	1
Monfort, JC	1
Duyckaerts, C	1
Kostić, VS	1
Djuricić, BM	1
Covicković-Sternić, N	1
Bumbasirević, L	1
Nikolić, M	1
Mrsulja, BB	1
Andersen, K	1
Balldin, J	1
Modigh, K	1
Svennerholm, L	1
Wallin, A	1
Thal, LJ	1
Cote, LJ	1
Nishi, K	1
Kondo, T	1
Takubo, H	1
Muramoto, S	1
Araki, H	1
Jankovic, J	1
Grossman, R	1
Goodman, C	1
Pirozzolo, F	1
Schneider, L	1
Zhu, Z	1
Scardino, P	1
Garber, AJ	1
Jhingran, SG	1
Martin, S	1
Broseta, J	1
Diaz-Cascajo, P	1
García-March, G	1
Sánchez-Ledesma, MJ	1
Dissing, IC	1
Güttler, F	1
Pakkenberg, H	2
Lou, H	1
Gerdes, AM	1
Lykkelund, C	1
Rasmussen, V	1
Rosenstein, R	1
Fukuda, H	1
Hara, K	1
Udaka, F	1
Kameyama, M	1
Kraus, P	1
Backlund, EO	1
Granberg, PO	1
Hamberger, B	1
Knutsson, E	1
Mårtensson, A	1
Sedvall, G	1
Seiger, A	1
Olson, L	1
Volicer, L	1
Direnfeld, LK	1
Freedman, M	1
Albert, ML	1
Langlias, PJ	1
Bird, ED	1
Stahl, SM	1
Faull, KF	1
Barchas, JD	1
Berger, PA	1
LeWitt, PA	1
Gibson, CJ	1
Collins, MA	1
Neafsey, EJ	1
Nies, A	1
Davis, JN	1
Bunney, WE	1
Davis, JM	1
Colburn, RW	1
Bourne, HR	1
Shaw, DM	1
Coppen, AJ	1
Sirtola, T	1
Minderhoud, JM	1
Schut, T	2
Casati, C	1
Coppen, A	1
Metcalfe, M	1
Carroll, JD	1
Morris, JG	1
Garelis, E	2
Sourkes, TL	3
Gordon, EK	5
Oliver, J	1
Schnur, JA	3
Brody, JA	3
Curzon, G	5
Gumpert, J	2
Sharpe, D	2
Papeschi, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease[NCT01676103]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2012-09-30	Completed
Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794]		61 participants (Actual)	Interventional	2010-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6

Apathy Evaluation Scale (AES)

Intervention	incidents of an adverse event (Number)
Double rTMS	18
M1 Active rTMS + DLPFC Sham rTMS	14
DLPFC Active rTMS + M1 Sham rTMS	1
Double Sham rTMS	1

To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Beck Depression Inventory (BDI-II)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	18.7	18.1	19.0	19.3	15.8
Double rTMS	15.6	16.2	17	16.9	17.8
Double Sham rTMS	16.3	15.5	15.0	16.1	16.2
M1 Active rTMS + DLPFC Sham rTMS	15.9	16.9	14.6	15.1	12.4

To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Clinical Anxiety Scale (CAS)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	21.7	18.2	20.2	19.0	15.7
Double rTMS	23.2	20.7	16.4	17.9	20.1
Double Sham rTMS	18.8	13.7	13.1	14.7	16.8
M1 Active rTMS + DLPFC Sham rTMS	18.5	16.5	16.7	19.1	16.3

To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Global Impression Scales

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	33.4	27.6	30.8	31.4	24.8
Double rTMS	36.3	34.2	31.7	33.1	33.4
Double Sham rTMS	37.5	32.4	28.2	28.5	35.0
M1 Active rTMS + DLPFC Sham rTMS	34.3	31.0	30.8	27.3	28.1

To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Hamilton Depression Scale (HAM-D)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment): Severity	Week 1 Post Treatment: Severity	Week 1 Post Treatment: Improvement	Month 1 Post Treatment: Severity	Month 1 Post Treatment: Improvement	Month 3 Post Treatment: Severity	Month 3 Post Treatment: Improvement	Month 6 Post Treatment: Severity	Month 6 Post Treatment: Improvement
DLPFC Active rTMS + M1 Sham rTMS	4.3	4.7	3.5	4.4	3.7	4.4	3.6	4.3	3.7
Double rTMS	4.9	4.8	3.6	4.4	3.5	4.6	3.7	4.2	3.5
Double Sham rTMS	3.6	3.9	3.0	4.1	3.5	4.4	3.6	4.6	3.4
M1 Active rTMS + DLPFC Sham rTMS	4.7	4.9	3.5	4.8	3.8	3.8	3.4	5.0	4.2

"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Montreal Cognitive Assessment (MoCA)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post-Treatment	Month 1 Post-Treatment	Month 3 Post-Treatment	Month 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS	13.8	9.4	12.4	10.4	10.4
Double rTMS	15.2	11.3	10.6	10.7	10.4
Double Sham rTMS	14.1	9.3	8.0	11.1	10.4
M1 Active rTMS + DLPFC Sham rTMS	16.7	11.2	10.1	10.1	8.6

To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment

Motor Subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	27.3	26.3	26.8	26.7	26.6
Double rTMS	28.2	26.8	28.8	26.5	28.0
Double Sham rTMS	26.2	27.8	28.7	24.9	28.0
M1 Active rTMS + DLPFC Sham rTMS	26.6	27.1	27.2	25.3	27.9

"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Parkinson's Disease Questionnaire 39 (PDQ-39)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post-Treatment	Month 1 Post-Treatment	Month 3 Post-Treatment	Month 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS	32.8	30.3	29.3	31.5	28.8
Double rTMS	32.3	31.2	30.1	29.6	30.5
Double Sham rTMS	28.9	28.2	28.6	28.6	29.0
M1 Active rTMS + DLPFC Sham rTMS	33.1	27.4	28.1	33.2	30.6

To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Unified Parkinson's Disease Rating Scale (UPDRS) Parts I, II, and IV

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	51.9	46.8	49.4	49.4	49
Double rTMS	57.6	51.2	49.9	51.7	50.5
Double Sham rTMS	55.5	43.1	40.9	43.1	47.5
M1 Active rTMS + DLPFC Sham rTMS	61.5	60.7	56.8	53.1	48.3

"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Article	Year
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis. Frontiers in immunology, 2022, Volume: 13 Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac	2022
Problems associated with fluid biomarkers for Parkinson's disease. Biomarkers in medicine, 2010, Volume: 4, Issue:5 Topics: alpha-Synuclein; Amyloid beta-Peptides; Biomarkers; Homovanillic Acid; Humans; Hydroxyindoleacetic A	2010
Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease. Neurologic clinics, 1984, Volume: 2, Issue:3 Topics: Adult; Aged; Dementia; Depression; Depressive Disorder; Homovanillic Acid; Humans; Huntington Diseas	1984
Early onset Parkinson's disease: are juvenile- and young-onset different? Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:5 Topics: Adolescent; Adult; Autonomic Nervous System; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic	1994
Amine precursors in neurologic disorders and the psychoses. Research publications - Association for Research in Nervous and Mental Disease, 1975, Volume: 54 Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo	1975
Changes in monoamine oxidase and monoamines with human development and aging. Federation proceedings, 1975, Volume: 34, Issue:1 Topics: Adult; Age Factors; Aged; Aging; Amines; Benzyl Compounds; Biogenic Amines; Blood Platelets; Brain;	1975
Depression and Parkinson's disease: a review. The American journal of psychiatry, 1992, Volume: 149, Issue:4 Topics: Biomarkers; Depressive Disorder; Dopamine; Female; Frontal Lobe; Functional Laterality; Humans; Hydr	1992
Affective disorders and aggression disorders: evidence for a common biological mechanism. Suicide & life-threatening behavior, 1986,Summer, Volume: 16, Issue:2 Topics: 5-Hydroxytryptophan; Aggression; Blood Platelets; Carrier Proteins; Celiac Disease; Depressive Disor	1986
[Modern treatment of parkinsonism]. Zeitschrift fur Neurologie, 1972, Volume: 202, Issue:4 Topics: Antiparkinson Agents; Brain Stem; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Female; Gastroin	1972
Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies. Brain research, 1974, Oct-11, Volume: 79, Issue:1 Topics: Animals; Biological Transport, Active; Brain; Cats; Cerebral Ventricles; Cerebrospinal Fluid; Choroi	1974
Serotonergic mechanisms and extrapyramidal function in man. Advances in neurology, 1974, Volume: 5 Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr	1974
[Biochemistry of depression]. Journal of neural transmission, 1972, Volume: 33, Issue:3 Topics: Animals; Bipolar Disorder; Brain; Central Nervous System; Depression; Dihydroxyphenylalanine; Glycol	1972
[Biochemical aspects of human behaviour (author's transl)]. Folia clinica internacional, 1973, Volume: 23, Issue:9 Topics: Animals; Athetosis; Behavior; Behavior, Animal; Biogenic Amines; Brain; Brain Chemistry; Catecholami	1973
Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain : a journal of neurology, 1970, Volume: 93, Issue:2 Topics: Amines; Animals; Basal Ganglia; Biological Transport, Active; Blood-Brain Barrier; Brain; Cerebral V	1970

Article	Year
Deprenyl in Parkinson disease. Neurology, 1981, Volume: 31, Issue:1 Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic	1981
The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. Journal of the neurological sciences, 1996, Volume: 139, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Biogenic Monoamines; Cerebral Ventricle	1996
Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease. Journal of neurology, 2001, Volume: 248 Suppl 3 Topics: Aged; Aged, 80 and over; Biogenic Monoamines; Electromagnetic Fields; Female; gamma-Aminobutyric Aci	2001
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism. Acta neurologica Scandinavica, 1975, Volume: 51, Issue:1 Topics: Aged; Antiparkinson Agents; Chorea; Clinical Trials as Topic; Confusion; Dioxoles; Dopamine; Drug Ev	1975
Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism. Advances in neurology, 1975, Volume: 9 Topics: Aged; Brain; Clinical Trials as Topic; Dopamine; Drug Evaluation; Drug Therapy, Combination; Female;	1975
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta neurologica Scandinavica, 1987, Volume: 76, Issue:3 Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Electroconvulsive Therapy; Female; Homovanillic	1987
The relationship of serotonin to depression in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1988, Volume: 3, Issue:3 Topics: 5-Hydroxytryptophan; Aged; Clinical Trials as Topic; Dementia; Depressive Disorder; Female; Humans;	1988
Tetrahydrobiopterin and Parkinson's disease. Acta neurologica Scandinavica, 1989, Volume: 79, Issue:6 Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; H	1989
Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. Journal of neurosurgery, 1985, Volume: 62, Issue:2 Topics: Adrenal Medulla; Caudate Nucleus; Clinical Trials as Topic; Corpus Striatum; Female; Homovanillic Ac	1985
Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Zeitschrift fur Neurologie, 1972, Volume: 202, Issue:1 Topics: Biopsy; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combinations; Drug Sy	1972
Levodopa and L-tryptophan therapy in Parkinsonism. Lancet (London, England), 1972, Mar-25, Volume: 1, Issue:7752 Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Gait; Homovanillic Acid; Humans; Hydroxyindoleacet	1972
[Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease]. Nature: New biology, 1972, Apr-19, Volume: 236, Issue:68 Topics: Adult; Aged; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamine; Evaluation Studies as Topic	1972
Treatment of Parkinson's disease with amantadine and L-Dopa. European neurology, 1972, Volume: 7, Issue:4 Topics: Adult; Aged; Alkaline Phosphatase; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Dru	1972
Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology, 1972, Volume: 22, Issue:5 Topics: 5-Hydroxytryptophan; Adult; Aged; Brain; Carboxy-Lyases; Clinical Trials as Topic; Drug Synergism; E	1972
Parkinson disease treated with a suspected dopamine receptor agonist. Archives of neurology, 1974, Volume: 30, Issue:5 Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla	1974
Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism. Neurology, 1972, Volume: 22, Issue:4 Topics: Adolescent; Adult; Aged; Blood Pressure; Brain; Child; Dihydroxyphenylalanine; Dopamine; Evaluation	1972

Article	Year
Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes. Neuro-degenerative diseases, 2021, Volume: 21, Issue:1-2 Topics: Diagnosis, Differential; Humans; Hydroxyindoleacetic Acid; Multiple System Atrophy; Parkinson Diseas	2021
Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. Neuroreport, 2023, Aug-24, Volume: 34, Issue:11 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Corpus Striatum; Disease Models, Ani	2023
Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection. Journal of pharmaceutical and biomedical analysis, 2018, May-10, Volume: 153 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Biomarkers; Chromatography, High Pressure	2018
Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. Journal of Parkinson's disease, 2018, Volume: 8, Issue:1 Topics: Aged; Biogenic Monoamines; Biomarkers; Cognition Disorders; Cognitive Dysfunction; Diagnosis, Differ	2018
Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:2 Topics: Animals; Brain; Dementia; Disease Models, Animal; Dopamine; Hydroxyindoleacetic Acid; Male; Memory;	2019
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. Journal of neurology, 2013, Volume: 260, Issue:12 Topics: Aged; Cerebrovascular Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male;	2013
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. PloS one, 2014, Volume: 9, Issue:7 Topics: Aged; Cohort Studies; Depression; Female; Humans; Hydroxyindoleacetic Acid; Male; Parkinson Disease;	2014
Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms. Parkinsonism & related disorders, 2015, Volume: 21, Issue:8 Topics: Aged; Biomarkers; Depression; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Pain; Par	2015
L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:8 Topics: Action Potentials; Animals; Antiparkinson Agents; Cholestanols; Citalopram; Disease Models, Animal;	2016
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. Journal of neurology, 2010, Volume: 257, Issue:4 Topics: Aged; Analysis of Variance; Biogenic Monoamines; Brain-Derived Neurotrophic Factor; Corticosterone;	2010
Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine. Journal of ethnopharmacology, 2010, Jul-06, Volume: 130, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Cor	2010
S100B transgenic mice develop features of Parkinson's disease. Archives of medical research, 2011, Volume: 42, Issue:1 Topics: Animals; Brain; Dopamine; G-Protein-Coupled Receptor Kinase 2; G-Protein-Coupled Receptor Kinase 5;	2011
6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. Brain research, 2012, Oct-05, Volume: 1477 Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Central Nervous System Stimulants; Cereb	2012
[Determination of urinary 5-hydroxyindolacetic acid in Parkinson's disease]. Revue canadienne de biologie, 1961, Volume: 20 Topics: Body Fluids; Hydroxyindoleacetic Acid; Indoleacetic Acids; Parkinson Disease; Urinary Tract	1961
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5 Topics: Adult; Aged; Benzamides; Brain; Diagnosis, Differential; Electromyography; Enzyme-Linked Immunosorbe	2004
Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. Neurology, 2004, May-25, Volume: 62, Issue:10 Topics: Dopamine; Dystonic Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Infant, N	2004
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced;	2008
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Basic & clinical pharmacology & toxicology, 2008, Volume: 102, Issue:3 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Rel	2008
CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. Brain research, 2008, Jan-29, Volume: 1191 Topics: Adenosine A2 Receptor Agonists; Animals; Behavior, Animal; Biogenic Monoamines; Caffeine; Disease Mo	2008
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep medicine, 2009, Volume: 10, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Monoamines; Chromatography, High Pressure Liquid; Cir	2009
5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life sciences, 1967, Jul-01, Volume: 6, Issue:13 Topics: Adult; Aged; Basal Ganglia; Brain Stem; Caudate Nucleus; Chemistry, Clinical; Dopamine; Humans; Hydr	1967
A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological Parkinsonism. Advances in biochemical psychopharmacology, 1980, Volume: 24 Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Homovanillic Acid; Humans; Hyd	1980
[Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)]. No to shinkei = Brain and nerve, 1980, Volume: 32, Issue:10 Topics: Adult; Aged; Animals; Brain Chemistry; Carboxy-Lyases; Dopamine; Drug Therapy, Combination; Female;	1980
Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. Neuropsychobiology, 1981, Volume: 7, Issue:3 Topics: Aged; Dementia; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti	1981
Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism. Advances in experimental medicine and biology, 1981, Volume: 133 Topics: Brain; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M	1981
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life sciences, 1982, Mar-08, Volume: 30, Issue:10 Topics: Administration, Oral; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Hydroxyindole	1982
Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment. Acta neurologica Scandinavica, 1982, Volume: 66, Issue:2 Topics: Aged; Cyclic AMP; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Metho	1982
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences of the United States of America, 1983, Volume: 80, Issue:14 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima	1983
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders. Advances in neurology, 1984, Volume: 40 Topics: Adult; Basal Ganglia Diseases; Cyclic AMP; Female; Homovanillic Acid; Humans; Huntington Disease; Hy	1984
Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology, 1984, Volume: 34, Issue:5 Topics: Aged; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyp	1984
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. Acta neurologica Scandinavica, 1984, Volume: 69, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression;	1984
Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism. Archives of neurology, 1984, Volume: 41, Issue:10 Topics: Aged; Arousal; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphenylgly	1984
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neuroscience letters, 1993, Sep-03, Volume: 159, Issue:1-2 Topics: Aged; Dopamine; Humans; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Middle Aged; Parkinson Disea	1993
Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neuroscience letters, 1993, Feb-05, Volume: 150, Issue:1 Topics: 5-Hydroxytryptophan; Humans; Hydroxyindoleacetic Acid; Kynurenine; Middle Aged; Parkinson Disease; R	1993
Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:3 Topics: Acoustic Stimulation; Adolescent; Adult; Aged; Evoked Potentials, Auditory, Brain Stem; Evoked Poten	1993
Variable phenotype of rapid-onset dystonia-parkinsonism. Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:2 Topics: Adolescent; Adult; Dopamine; Dystonia; Female; Follow-Up Studies; Genetic Carrier Screening; Homovan	1996
Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa. Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:5 Topics: Aged; Aged, 80 and over; Aging; Biogenic Monoamines; Dementia; Female; Homovanillic Acid; Humans; Hy	1996
Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Experimental neurology, 1997, Volume: 145, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dis	1997
Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. Journal of neural transmission (Vienna, Austria : 1996), 1997, Volume: 104, Issue:4-5 Topics: 5-Hydroxytryptophan; Aged; Biogenic Amines; Cerebral Ventricles; Gait; Homovanillic Acid; Humans; Hy	1997
Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. Annals of neurology, 1998, Volume: 43, Issue:4 Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Deglutition Disorders; Dopamine; Dysarthria; Dystonia	1998
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Progress in neuro-psychopharmacology & biological psychiatry, 1998, Volume: 22, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Depressive Disorder; Dopamine; Electric Stimulation; Electr	1998
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:4 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catecholamines; Female; Hallucinations	1996
ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:2-3 Topics: Aged; Aged, 80 and over; Biogenic Monoamines; Electroconvulsive Therapy; Female; Homovanillic Acid;	1995
Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology, 1999, Mar-10, Volume: 52, Issue:4 Topics: Aged; Aged, 80 and over; Disease Susceptibility; Female; Homovanillic Acid; Humans; Hydroxyindoleace	1999
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease. Neurobiology of disease, 1999, Volume: 6, Issue:1 Topics: Aged; Antiparkinson Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Progressi	1999
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat. Neuroscience letters, 2000, Dec-22, Volume: 296, Issue:2-3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Denervation; Dopamine; Electric Stimulation Therapy; Globus	2000
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse. Brain research, 2001, Jul-13, Volume: 907, Issue:1-2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru	2001
Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid. Neurology, 1976, Volume: 26, Issue:10 Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Hu	1976
Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea. Transactions of the American Neurological Association, 1976, Volume: 101 Topics: Bromocriptine; Ergolines; Growth Hormone; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo	1976
[Monamines (1): post-mortem studies of monoamines and related enzymes in the human brain]. Lakartidningen, 1978, Feb-22, Volume: 75, Issue:8 Topics: Age Factors; Aged; Autopsy; Brain; Catecholamines; Dementia; Dissection; Female; Freezing; Humans; H	1978
[Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects]. Nederlands tijdschrift voor geneeskunde, 1975, Sep-06, Volume: 119, Issue:36 Topics: Basal Ganglia; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle Aged;	1975
Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. Neurology, 1978, Volume: 28, Issue:12 Topics: Adult; Aged; Cerebral Palsy; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle A	1978
Progressive dystonia with marked diurnal fluctuation. Annals of neurology, 1978, Volume: 4, Issue:5 Topics: Child; Circadian Rhythm; Diagnosis, Differential; Dystonia; Female; Homovanillic Acid; Humans; Hydro	1978
Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism. Neurology, 1977, Volume: 27, Issue:6 Topics: Animals; Brain; Bromocriptine; Carbidopa; Dopamine; Drug Interactions; Ergolines; gamma-Aminobutyric	1977
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of neurology, neurosurgery, and psychiatry, 1977, Volume: 40, Issue:12 Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans;	1977
Juvenile parkinsonism: a patient with possible primary striatal dysfunction. Annals of neurology, 1978, Volume: 3, Issue:5 Topics: Adolescent; Corpus Striatum; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Parkinson Di	1978
L-deprenyl treatment of on-off phenomena in Parkinson's disease. Journal of neural transmission, 1978, Volume: 43, Issue:3-4 Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyin	1978
Juvenile parkinsonism treated with levodopa. Archives of neurology, 1977, Volume: 34, Issue:4 Topics: Age Factors; Child; Child, Preschool; Drug Evaluation; Female; Homovanillic Acid; Humans; Hydroxyind	1977
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602. European journal of clinical pharmacology, 1977, Apr-20, Volume: 11, Issue:4 Topics: Benserazide; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindole	1977
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. Journal of the neurological sciences, 1977, Volume: 32, Issue:2 Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines;	1977
Brain dopamine turnover and the relief of parkinsonism. Archives of neurology, 1977, Volume: 34, Issue:10 Topics: Brain; Bromocriptine; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disea	1977
Brain dopamine turnover and the relief of parkinsonism. Advances in experimental medicine and biology, 1977, Volume: 90 Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Homovanillic Acid; Humans; Hydroxyindol	1977
Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication. Advances in neurology, 1976, Volume: 14 Topics: Adolescent; Adult; Aged; Dopamine beta-Hydroxylase; Dystonia Musculorum Deformans; Female; Growth Ho	1976
[Striato-nigral degeneration. A propos of 2 anatomo-clinical cases]. Revue neurologique, 1976, Volume: 132, Issue:1 Topics: Brain Diseases; Corpus Striatum; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male;	1976
Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases. European neurology, 1975, Volume: 13, Issue:3 Topics: 5-Hydroxytryptophan; Aged; Amines; Brain Diseases; Female; Ganglia, Autonomic; Humans; Hydroxyindole	1975
Dopaminergic supersensitivity in parkinsonism. Advances in neurology, 1975, Volume: 9 Topics: Aged; Benzyl Compounds; Brain; Brain Chemistry; Dopamine; Drug Therapy, Combination; Female; Humans;	1975
Dopaminergic mechanisms in patients with extrapyramidal disease. Advances in neurology, 1975, Volume: 9 Topics: Animals; Biogenic Amines; Brain; Caffeine; Clonidine; Dopamine; Drug Evaluation; Drug Therapy, Combi	1975
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. Clinical neurology and neurosurgery, 1975, Volume: 78, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H	1975
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies. Journal of neural transmission. Supplementum, 1992, Volume: 38 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson	1992
Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta neuropathologica, 1992, Volume: 83, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Astrocytoma; Biopsy; Catecholamines; Caudate Nucleus; Child;	1992
Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport, 1992, Volume: 3, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic A	1992
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. Journal of the American Geriatrics Society, 1990, Volume: 38, Issue:1 Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Cognition Disorders; Female; Homovanillic Acid;	1990
Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism. Journal of neurochemistry, 1990, Volume: 54, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Carotid Arteries; Do	1990
[5-Hydroxyindole acetic acid assay and the clinical significance]. Nihon rinsho. Japanese journal of clinical medicine, 1990, Volume: 48 Suppl Topics: Anorexia Nervosa; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Depressive Dis	1990
Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia. Advances in neurology, 1990, Volume: 53 Topics: Dystonia Musculorum Deformans; Enkephalin, Methionine; Homovanillic Acid; Humans; Huntington Disease	1990
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid. Advances in neurology, 1990, Volume: 53 Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Le	1990
Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites. Progress in brain research, 1990, Volume: 82 Topics: Adrenal Medulla; Amnion; Animals; Brain Tissue Transplantation; Caudate Nucleus; Disease Models, Ani	1990
The threshold of pain and neurotransmitter's change on pain in Parkinson's disease. The Japanese journal of psychiatry and neurology, 1990, Volume: 44, Issue:3 Topics: Aged; beta-Endorphin; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydr	1990
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neuroscience letters, 1991, Feb-11, Volume: 123, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin	1991
Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Autopsy; Bio	1991
Tritiated imipramine binding. A peripheral marker for serotonin in Parkinson's disease. Archives of neurology, 1991, Volume: 48, Issue:10 Topics: Aged; Biomarkers; Blood Platelets; Depression; Humans; Hydroxyindoleacetic Acid; Imipramine; Middle	1991
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Annals of the New York Academy of Sciences, 1991, Volume: 640 Topics: Adult; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Hallucinatio	1991
Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus. Neuroscience letters, 1985, May-14, Volume: 56, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Amines; Corticotropin-Releasing Hormone; Dopamine; Fe	1985
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. Journal of neurochemistry, 1986, Volume: 46, Issue:5 Topics: Aged; Amines; Brain; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Indans; Kynuramine; Male; M	1986
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments. Brain research, 1986, Mar-05, Volume: 367, Issue:1-2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn	1986
[Neurotransmitters and degenerative diseases in the central nervous system]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1986, Volume: 23, Issue:1 Topics: Acetylcholinesterase; Aged; Aging; Brain Diseases; Dementia; Dopamine; Homovanillic Acid; Humans; Hy	1986
Clinical and biochemical features of depression in Parkinson's disease. The American journal of psychiatry, 1986, Volume: 143, Issue:6 Topics: Aged; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindoleac	1986
Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain research, 1986, Aug-13, Volume: 380, Issue:1 Topics: Aged; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Nerve Degeneratio	1986
Depression and Parkinson's disease. Advances in neurology, 1987, Volume: 45 Topics: Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydrocortisone; Hydro	1987
Depression and Parkinson's disease: possible role of serotonergic mechanisms. Journal of neurology, 1987, Volume: 234, Issue:2 Topics: Aged; Depressive Disorder; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Parkinson Di	1987
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology, 1987, Volume: 37, Issue:7 Topics: Aged; Alzheimer Disease; Arousal; Attention; Biogenic Amines; Cognition Disorders; Homovanillic Acid	1987
Diminished levels of ventricular fluid norepinephrine metabolite and somatostatin in childhood-onset dystonia. Advances in neurology, 1988, Volume: 50 Topics: Adolescent; Adult; Age Factors; Cerebral Palsy; Child; Child, Preschool; Dystonia; Homovanillic Acid	1988
Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid. Journal of the neurological sciences, 1989, Volume: 92, Issue:1 Topics: Aged; Biomarkers; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Metho	1989
Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology, 1989, Volume: 39, Issue:9 Topics: Activities of Daily Living; Adrenal Medulla; Caudate Nucleus; Follow-Up Studies; Homovanillic Acid;	1989
Critical approach to intrastriatal medullary adrenal implants via open surgery in parkinsonism. Case report. Acta neurochirurgica. Supplementum, 1989, Volume: 46 Topics: Adrenal Medulla; Aged; Caudate Nucleus; Graft Survival; Homovanillic Acid; Humans; Hydroxyindoleacet	1989
Coexisting dementia and depression in Parkinson's disease. Archives of neurology, 1989, Volume: 46, Issue:12 Topics: Aged; Aging; Alzheimer Disease; Dementia; Depression; Humans; Hydroxyindoleacetic Acid; Middle Aged;	1989
[Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases]. Rinsho shinkeigaku = Clinical neurology, 1989, Volume: 29, Issue:9 Topics: Adult; Aged; Alzheimer Disease; Brain Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxyin	1989
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanill	1989
Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. Archives of neurology, 1985, Volume: 42, Issue:2 Topics: Aged; Alzheimer Disease; Dementia; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Serotonin	1985
CSF monamine metabolites in movement disorders and normal aging. Archives of neurology, 1985, Volume: 42, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Female; Glycols; Ho	1985
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The New England journal of medicine, 1985, May-30, Volume: 312, Issue:22 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic	1985
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease. Archives of neurology, 1985, Volume: 42, Issue:5 Topics: Adult; Aged; Alzheimer Disease; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid	1985
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neuroscience letters, 1985, Apr-09, Volume: 55, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg	1985
Ageing, monoamines, and monoamine-oxidase levels. Lancet (London, England), 1972, Feb-05, Volume: 1, Issue:7745 Topics: Adult; Aged; Aging; Autopsy; Blood Platelets; Brain Chemistry; Cerebellum; Depression; Humans; Hydro	1972
Clinical significance of probenecid test. Lancet (London, England), 1973, Mar-17, Volume: 1, Issue:7803 Topics: Brain Diseases; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetat	1973
On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease. Zeitschrift fur Neurologie, 1973, Apr-02, Volume: 204, Issue:2 Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Male; Middl	1973
Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man. Journal of neurology, neurosurgery, and psychiatry, 1974, Volume: 37, Issue:6 Topics: Adolescent; Adult; Brain Diseases; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Female; Homovani	1974
3 -Methoxy- 4 -hydroxyphenylethylene glycol in human cerebrospinal fluid. Clinica chimica acta; international journal of clinical chemistry, 1971, Volume: 35, Issue:1 Topics: Chromatography, Gas; Depression; Dihydroxyphenylalanine; Down Syndrome; Ethers; Glycols; Humans; Hyd	1971
Parkinsonism-dementia of Guam: treatment with L-dopa. Neurology, 1971, Volume: 21, Issue:12 Topics: Adult; Dementia; Dihydroxyphenylalanine; Drug Eruptions; Female; Humans; Hydroxyindoleacetic Acid; H	1971
Amine metabolites in the cerbrospinal fluid in Huntington's chorea. Journal of neurology, neurosurgery, and psychiatry, 1972, Volume: 35, Issue:4 Topics: Adult; Aged; Dopamine; Female; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Male; Mental Di	1972
Serotonergic mechanisms in Parkinson's disease. Archives of neurology, 1972, Volume: 27, Issue:4 Topics: Aged; Brain; Female; Fenclonine; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Parkinson Dise	1972
The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases. Neurology, 1972, Volume: 22, Issue:11 Topics: Adolescent; Adult; Basal Ganglia Diseases; Cerebral Palsy; Cerebral Ventricles; Diazepam; Dihydroxyp	1972
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. Journal of neurochemistry, 1973, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Carbon Radioisotopes; Cerebrospinal Fluid; Child;	1973
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists. Archives of neurology, 1973, Volume: 29, Issue:5 Topics: Adult; Basal Ganglia Diseases; Brain; Central Nervous System Diseases; Dopamine; Haloperidol; Homova	1973
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans. Nature, 1974, Apr-19, Volume: 248, Issue:5450 Topics: Amino Acids; Blood Proteins; Brain; Diet; Eating; Fasting; Feeding Behavior; Humans; Huntington Dise	1974
Involuntary movements other than Parkinsonism: biochemical aspects. Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:9 Topics: Acute Disease; Animals; Athetosis; Basal Ganglia; Brain; Dopamine; Fecal Incontinence; Homovanillic	1973
Some remarks concerning the possible role of brain monoamines (dopamine, noradrenaline, serotonin) in mental disorders. Journal of psychiatric research, 1974, Volume: 11 Topics: Brain; Caudate Nucleus; Depression; Dopamine; Globus Pallidus; Humans; Huntington Disease; Hydroxyin	1974
Dopaminergic nervous transmission in Parkinson's disease. Medical biology, 1974, Volume: 52, Issue:3 Topics: Acetylcholinesterase; Aromatic Amino Acid Decarboxylase Inhibitors; Autopsy; Brain; Brain Chemistry;	1974
Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy. European neurology, 1974, Volume: 12, Issue:5-6 Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Depression, Chemical; Dopa Decarboxylase; Drug C	1974
Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease. Neurology, 1974, Volume: 24, Issue:10 Topics: Dietary Proteins; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levod	1974
Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology, 1972, Volume: 22, Issue:1 Topics: Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Parkinson Disease; Phenylacetates; Prob	1972
The balance of biogenic amines as condition for normal behaviour. Journal of neural transmission, 1972, Volume: 33, Issue:2 Topics: Aged; Benzyl Compounds; Brain; Dihydroxyphenylalanine; Dopamine; Electroencephalography; Female; Hum	1972
Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects. Journal of the neurological sciences, 1972, Volume: 17, Issue:3 Topics: Adult; Aged; Amantadine; Catecholamines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Hist	1972
Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF. Confinia neurologica, 1972, Volume: 34, Issue:2 Topics: Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Microscopy, F	1972
Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects. British journal of pharmacology, 1972, Volume: 44, Issue:2 Topics: Amantadine; Amines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Histamine; Homovanillic Acid; Hum	1972
Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. European neurology, 1973, Volume: 9, Issue:6 Topics: Adult; Aged; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Dru	1973
Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. Journal of the neurological sciences, 1973, Volume: 19, Issue:1 Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Electroencephalogra	1973
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. Journal of the neurological sciences, 1973, Volume: 19, Issue:3 Topics: Basal Ganglia; Carboxy-Lyases; Cerebellum; Cerebral Cortex; Corpus Striatum; Diencephalon; Dihydroxy	1973
Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances. Acta medica Scandinavica, 1973, Volume: 194, Issue:3 Topics: Aged; Brain; Dementia; Depression, Chemical; Dihydroxyphenylalanine; Female; Humans; Hydroxyindoleac	1973
5-Hydroxyindoleacetic acid in cerebrospinal fluid. Acta medica Academiae Scientiarum Hungaricae, 1973, Volume: 30, Issue:3 Topics: Adult; Age Factors; Brain Diseases; Brain Stem; Depression; Epilepsy; Humans; Hydroxyindoleacetic Ac	1973
Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine. Therapia Hungarica (English edition), 1973, Volume: 21, Issue:1 Topics: Amantadine; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson D	1973
Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. The Quarterly journal of medicine, 1974, Volume: 43, Issue:169 Topics: Aged; Dementia; Dihydroxyphenylalanine; Electroencephalography; Female; Gait; Homovanillic Acid; Hum	1974
Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease. The British journal of psychiatry : the journal of mental science, 1974, Volume: 124, Issue:0 Topics: Affective Symptoms; Aged; Bicarbonates; Carbon Dioxide; Dementia; Female; Glycolysis; Homovanillic A	1974
Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings. Journal of neural transmission, 1974, Volume: 35, Issue:2 Topics: Aged; Amygdala; Autopsy; Biogenic Amines; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine;	1974
Viral infections in the central nervous system and 5-hydroxytryptamine metabolism. Advances in biochemical psychopharmacology, 1974, Volume: 11, Issue:0 Topics: Animals; Brain; Brain Diseases; Catecholamines; Coxsackievirus Infections; Dopamine; Encephalitis; H	1974
Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism. European journal of clinical pharmacology, 1974, Volume: 7, Issue:2 Topics: Age Factors; Aged; Biogenic Amines; Depression; Dihydroxyphenylalanine; Emotions; Female; Homovanill	1974
Fusaric acid in Parkinson's disease. Neurology, 1974, Volume: 24, Issue:7 Topics: Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homovanillic Acid; Humans; Hydroxyindole	1974
Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase, affects serotonin and noradrenaline. Nature, 1971, May-07, Volume: 231, Issue:5297 Topics: Animals; Brain; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Hydroxyindoleacetic Acid; Male; M	1971
[Effect of diphenylhydantoin on the clinical manifestations and excretion of 5-hydroxyindoloacetic acid in Parkinson's disease]. Neurologia i neurochirurgia polska, 1972, Volume: 6, Issue:3 Topics: Adult; Aged; Brain; Humans; Hydroxyindoleacetic Acid; Middle Aged; Muscle Tonus; Parkinson Disease;	1972
Catecholamine metabolism during oral administration of levodopa. Archives of neurology, 1972, Volume: 26, Issue:3 Topics: Aged; Catecholamines; Dihydroxyphenylalanine; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Ma	1972
Central monoamine metabolism in Parkinson's disease. Archives of neurology, 1972, Volume: 27, Issue:6 Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Evaluation Studies as Topic; Female; Humans; Hydroxyi	1972
Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF. Confinia neurologica, 1972, Volume: 34, Issue:1 Topics: Caudate Nucleus; Dihydroxyphenylalanine; Humans; Hydroxyindoleacetic Acid; Microscopy, Fluorescence;	1972
Effects of L-DOPA treatment on indole metabolism in Parkinson's disease. Experientia, 1971, May-15, Volume: 27, Issue:5 Topics: Depression, Chemical; Dihydroxyphenylalanine; Humans; Hydroxyindoleacetic Acid; Indoleacetic Acids;	1971
The distribution of 5-hydroxyindoleacetic acid in various animals and its fluorometric analysis in diverse biological material. The Journal of pharmacology and experimental therapeutics, 1971, Volume: 179, Issue:2 Topics: Amniotic Fluid; Animals; Brain Chemistry; Cats; Chromatography; Chromatography, Paper; Dogs; Fluorom	1971
Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid. Archives of neurology, 1971, Volume: 25, Issue:1 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Dihydroxyphenylalanine; Dopamine; Female; Humans; Hydrox	1971
5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa. European journal of clinical pharmacology, 1971, Volume: 3, Issue:4 Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Pa	1971
Amine metabolites in the lumbar cerebrospinal fluid of humans with restricted flow of cerebrospinal fluid. Nature: New biology, 1971, Jun-09, Volume: 231, Issue:23 Topics: Brain; Dopamine; Humans; Hydroxyindoleacetic Acid; Intervertebral Disc Displacement; Lumbosacral Reg	1971
The effect of L-dopa on monoamine metabolites in Parkinson's disease. Experientia, 1970, Volume: 26, Issue:2 Topics: 5-Hydroxytryptophan; Aged; Dihydroxyphenylalanine; Dopamine; Humans; Hydroxyindoleacetic Acid; Middl	1970
Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease. Mayo Clinic proceedings, 1970, Volume: 45, Issue:9 Topics: 5-Hydroxytryptophan; Adult; Aged; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Female; Huma	1970
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. Neurology, 1970, Volume: 20, Issue:12 Topics: 5-Hydroxytryptophan; Adult; Aromatic Amino Acid Decarboxylase Inhibitors; Dihydroxyphenylalanine; Dr	1970
Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology, 1970, Volume: 9, Issue:3 Topics: Amines; Brain; Chlorpromazine; Extrapyramidal Tracts; Female; Humans; Hydroxyindoleacetic Acid; Move	1970
Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam. The New England journal of medicine, 1970, Apr-23, Volume: 282, Issue:17 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Brain; Dementia; Dopamine; Humans; Hydroxyindoleacetic A	1970
[Clinical pharmacology (11): diagnostic methods]. Lakartidningen, 1970, Apr-29, Volume: 67, Issue:18 Topics: Bipolar Disorder; Diagnostic Uses of Chemicals; Humans; Hydroxyindoleacetic Acid; Parkinson Disease;	1970
Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease. Neurology, 1970, Volume: 20, Issue:4 Topics: Dementia; Dihydroxyphenylalanine; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetate	1970
Uptake of catecholamines into serotonergic nerve cells as demonstrated by fluorescence histochemistry. Experientia, 1971, Volume: 27, Issue:6 Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Binding Sites; Catecholamines; Dihydroxypheny	1971
Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF. Journal of neurology, neurosurgery, and psychiatry, 1971, Volume: 34, Issue:3 Topics: Aged; Arteriosclerosis; Dihydroxyphenylalanine; Female; Humans; Hydroxyindoleacetic Acid; Male; Park	1971
Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease. Life sciences. Pt. 1: Physiology and pharmacology, 1971, May-15, Volume: 10, Issue:10 Topics: Aged; Amines; Brain Chemistry; Cerebellar Cortex; Cerebral Cortex; Dihydroxyphenylalanine; Dopamine;	1971
On the occurrence of homovanillic acid and 5-hydroxyindol-3-ylacetic acid in the ventricular C.S.F. of patients suffering from parkinsonism. Confinia neurologica, 1967, Volume: 29, Issue:2 Topics: Cerebral Ventricles; Female; Humans; Hydroxyindoleacetic Acid; Male; Parkinson Disease; Parkinson Di	1967
Indolealkylamines and behavior. Introductory remarks. Advances in pharmacology, 1968, Volume: 6, Issue:Pt B Topics: Animals; Behavior; Depression; Dogs; Humans; Hydroxyindoleacetic Acid; Indoles; Parkinson Disease; P	1968
Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease. Nature, 1968, Aug-03, Volume: 219, Issue:5153 Topics: Aged; Chemistry, Clinical; Female; Humans; Hydroxyindoleacetic Acid; Intracranial Arteriosclerosis;	1968
Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. Journal of neurochemistry, 1969, Volume: 16, Issue:9 Topics: Adult; Aged; Amines; Brain; Dementia; Humans; Hydroxyindoleacetic Acid; Middle Aged; Parkinson Disea	1969
Dopamine and basal ganglia disorders. Neurology, 1965, Volume: 15, Issue:11 Topics: Adult; Basal Ganglia; Dopamine; Female; Hepatolenticular Degeneration; Humans; Hydroxyindoleacetic A	1965
Urinary amines in patients undergoing thalamotomy for Parkinson's disease. Neurology, 1966, Volume: 16, Issue:6 Topics: Adult; Chromatography, Paper; Dopamine; Electrocoagulation; Humans; Hydroxyindoleacetic Acid; Middle	1966

hydroxyindoleacetic acid and Parkinson Disease